CA2232002A1 - Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes - Google Patents

Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes Download PDF

Info

Publication number
CA2232002A1
CA2232002A1 CA002232002A CA2232002A CA2232002A1 CA 2232002 A1 CA2232002 A1 CA 2232002A1 CA 002232002 A CA002232002 A CA 002232002A CA 2232002 A CA2232002 A CA 2232002A CA 2232002 A1 CA2232002 A1 CA 2232002A1
Authority
CA
Canada
Prior art keywords
presenting cells
cells
antigen presenting
human
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232002A
Other languages
English (en)
French (fr)
Inventor
Pramod K. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fordham University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232002A1 publication Critical patent/CA2232002A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002232002A 1995-09-13 1996-09-11 Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes Abandoned CA2232002A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/527,546 US5985270A (en) 1995-09-13 1995-09-13 Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US527,546 1995-09-13
PCT/US1996/014558 WO1997010002A1 (en) 1995-09-13 1996-09-11 Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes

Publications (1)

Publication Number Publication Date
CA2232002A1 true CA2232002A1 (en) 1997-03-20

Family

ID=24101899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232002A Abandoned CA2232002A1 (en) 1995-09-13 1996-09-11 Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes

Country Status (12)

Country Link
US (2) US5985270A (enExample)
EP (1) EP0857068B1 (enExample)
JP (1) JPH11512433A (enExample)
AT (1) ATE264910T1 (enExample)
AU (1) AU728929B2 (enExample)
CA (1) CA2232002A1 (enExample)
DE (1) DE69632261T2 (enExample)
DK (1) DK0857068T3 (enExample)
ES (1) ES2219696T3 (enExample)
PT (1) PT857068E (enExample)
WO (1) WO1997010002A1 (enExample)
ZA (1) ZA967756B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105176957A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 肾癌相关肽和热休克蛋白形成的复合物及其应用

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
EP0888053A4 (en) 1995-08-18 2002-07-31 Sloan Kettering Inst Cancer METHOD FOR TREATING CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS THAT CAN BE USED THEREFOR
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
EP0950061A4 (en) 1996-09-20 2000-04-12 Univ New Mexico Heat shock protein complexes
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
BR9812272A (pt) * 1997-08-05 2000-07-18 Stressgen Biotechnologies Corp Respostas imunológicas contra antìgenos de hpv, eliciadas por composições que compreendem um antìgeno de hpv e uma proteìna de tensão ou um vetor de expressão capaz de expressar essas proteìnas
CA2308299A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1054683B1 (en) 1998-02-20 2007-04-11 University Of Miami Modified heat shock protein-antigenic peptide complex
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
CA2320491A1 (en) 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US6858386B1 (en) 1998-05-21 2005-02-22 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
ATE351905T1 (de) * 1998-11-10 2007-02-15 Univ Emory Mitogene regulatoren
US6730302B1 (en) * 1998-11-24 2004-05-04 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kD heat shock protein
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1250149A4 (en) * 1999-11-22 2003-06-04 Diadexus Inc NEW METHOD FOR DIAGNOSIS, MONITORING, STADIFYING, IMAGING AND TREATING CANCER
US7238471B1 (en) 1999-11-23 2007-07-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US20020048777A1 (en) * 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
EP1237570A4 (en) * 1999-12-15 2005-01-05 Peptor Ltd FRAGMENTS AND ANTAGONISTS OF THERMAL SHOCK PROTEINS 60
IL150113A0 (en) * 1999-12-15 2002-12-01 Peptor Ltd Fragments and antagonists of heat shock protein 60
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
WO2001092528A2 (en) * 2000-05-26 2001-12-06 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU2001266694C1 (en) 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
JP2004524820A (ja) * 2000-09-15 2004-08-19 ユニバーシティー オブ コネティカット ヘルス センター 熱ショック／ストレスタンパク質−ペプチド複合体
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
WO2002057795A2 (en) 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis
EP1357940A4 (en) 2001-02-05 2004-03-17 Stressgen Biotechnologies Corp HEPATITIS? B? VIRUS THERAPY
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
PT1377251E (pt) 2001-02-20 2008-08-05 Ortho Mcneil Janssen Pharm Método de terapia celular para o tratamento de tumores
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP1425039A4 (en) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
CN1635896A (zh) * 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
JP2005512519A (ja) 2001-10-01 2005-05-12 デューク・ユニバーシティ 単離ｇｒｐ９４リガンド結合ドメインポリペプチドおよびそれをコードする核酸、その結晶、およびそれを用いるスクリーニング方法
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
EP1575479A4 (en) 2002-01-31 2006-10-25 Develogen Israel Ltd HSP-PEPTIDES AND ANALOGUES FOR MODULATING IMMUNE RESPONSES ON ANY PRESENTING CELLS
US7118753B2 (en) * 2002-02-08 2006-10-10 Anawrahta Biotech Co., Ltd. Enhancing cell-based immunotherapy
JP2005530487A (ja) * 2002-02-28 2005-10-13 アンティジェニクス インコーポレーテッド ストレスタンパク質のオリゴマー化に基づく方法および生成物
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
IL164799A0 (en) * 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US20060093612A1 (en) * 2002-05-02 2006-05-04 Srivastava Pramod K Use of heat shock proteins to enhance efficacy of antibody therapeutics
US20050158328A1 (en) 2002-06-06 2005-07-21 Immunicum Ab Method and composition for producing a cellular allogeneic vaccine
EP1576124A2 (en) * 2002-10-07 2005-09-21 Antigenics Inc. Heat shock protein binding fragments of cd91, and uses thereof
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
CN1764375A (zh) * 2003-02-20 2006-04-26 康涅狄格大学健康中心 使用包括热休克蛋白或α－2－巨球蛋白的组合物治疗癌症和传染病的方法
ATE491463T1 (de) 2003-02-20 2011-01-15 Univ Connecticut Health Ct Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
US20040258705A1 (en) * 2003-02-28 2004-12-23 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
JP2011513399A (ja) 2008-03-03 2011-04-28 ザ ユニバーシティー オブ マイアミ 同種癌細胞による免疫療法
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
BRPI0914684C1 (pt) 2008-06-26 2021-05-25 Orphazyme As uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
US20110236345A1 (en) * 2008-07-03 2011-09-29 Duke University Composition and methods for eliciting an immune response
US20110223196A1 (en) * 2008-11-21 2011-09-15 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity
JP2012510284A (ja) 2008-12-03 2012-05-10 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ ワクチンの開発のためのフェノール可溶性モジュリンの使用
WO2010115118A2 (en) 2009-04-03 2010-10-07 Antigenics, Inc. Methods for preparing and using multichaperone-antigen complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3922242A1 (en) 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomol formulation
JP6744318B2 (ja) 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (pt) 2016-04-29 2019-02-05 Orphazyme As ingrediente farmacêutico ativo, e, composição
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
AU2021380947C1 (en) 2020-11-19 2025-02-20 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
ATE127345T1 (de) * 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
DE69126668T2 (de) * 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FI944102A7 (fi) * 1992-03-09 1994-09-07 Istituto Naz Per Lo Studio E La Kasvaimen kasvua estämään kykenevä proteiiniyhdiste
WO1993021529A1 (en) * 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5680984A (en) * 1994-05-13 1997-10-28 Matsushita Electric Industrial Co., Ltd. Apparatus and method for mounting soldering balls onto surfaces of electronic components
DE19502985A1 (de) * 1995-01-31 1996-08-01 Deutsche Telekom Ag Steckverbindung für ein optisches Bauelement
EP0888053A4 (en) * 1995-08-18 2002-07-31 Sloan Kettering Inst Cancer METHOD FOR TREATING CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS THAT CAN BE USED THEREFOR
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105176957A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 肾癌相关肽和热休克蛋白形成的复合物及其应用

Also Published As

Publication number Publication date
DE69632261D1 (de) 2004-05-27
US5985270A (en) 1999-11-16
AU6973596A (en) 1997-04-01
DE69632261T2 (de) 2005-04-14
WO1997010002A1 (en) 1997-03-20
ATE264910T1 (de) 2004-05-15
ZA967756B (en) 1997-04-16
US6156302A (en) 2000-12-05
EP0857068A1 (en) 1998-08-12
DK0857068T3 (da) 2004-08-16
JPH11512433A (ja) 1999-10-26
AU728929B2 (en) 2001-01-18
EP0857068B1 (en) 2004-04-21
ES2219696T3 (es) 2004-12-01
PT857068E (pt) 2004-09-30
EP0857068A4 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AU728929B2 (en) Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes
AU742986B2 (en) Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes forprevention/treatment of cancer or infectious diseases
US6017540A (en) Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
AU703101B2 (en) Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins
US5935576A (en) Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
EP0851765A1 (en) Therapeutic and prophylactic methods using heat shock proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20070911